Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness
| Autor: | Brian Harris, H. Cody Meissner, Kari A. Simonsen, Genevieve A. Losonsky, Adrian Trenholme, Charissa McBride-Miller, Maria Del Pilar Fernandez Fraile, Jose Manuel Pascual Novoa Pizarro, Dwight A. Powell, Elizabeth Castaño, Pablo J. Sánchez, Felice C. Adler-Shohet, Michael D. Nissen, Cecilia A. Silva, C. Kathy Wang, Susana Chavez-Bueno, Octavio Ramilo, Philip Jeffrey Brown, Xavier Sáez-Llorens, Sandra Lanceley, Sana Rettig, Rosanna Lagos, Asuncion Mejias, Karen Murray, Jose R. Romero, Katia Gabriela Abarca Villaseca, C. Lucy Park, Rehka Bandepalli, JoAnn Suzich, Ioulia Sakovets, M. Pamela Griffin, Rosanna Marietta Lagos Zuccone, Nan O'donnell, Raymond Chuk, Jay M. Leiberman, Kwabena Krow Ampofo, Maria Isabel Ibanez, Chris Stockmann, Kathryn M Jensen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Microbiology (medical)
Male viruses Respiratory Syncytial Virus Infections Antibodies Monoclonal Humanized Real-Time Polymerase Chain Reaction Antiviral Agents Severity of Illness Index Virus Placebos Motavizumab Severity of illness Medicine Humans Longitudinal Studies Respiratory system biology business.industry Reverse Transcriptase Polymerase Chain Reaction Infant Newborn Infant Length of Stay Viral Load Infectious Diseases medicine.anatomical_structure Treatment Outcome Respiratory Syncytial Virus Human Pediatrics Perinatology and Child Health Monoclonal Immunology biology.protein Female Antibody Nasal Cavity business Viral load medicine.drug Respiratory tract |
| Zdroj: | The Pediatric infectious disease journal. 33(7) |
| ISSN: | 1532-0987 |
| Popis: | This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respiratory tract infection.Infants hospitalized with lower respiratory tract infection and a positive RSV test performed locally were randomized to receive 1 intravenous dose of motavizumab (30 or 100 mg/kg) or placebo. Nasal wash samples were tested by real-time reverse transcriptase polymerase chain reaction at a central laboratory to determine viral load. Clinical data were collected during RSV hospitalization and at 12-month follow up.Of 118 infants, 112 were confirmed RSV positive by real-time reverse transcriptase polymerase chain reaction. In each study group, median (range) RSV load (log10 copies/mL) decreased at a similar rate from baseline to study day 7 [motavizumab 30 mg/kg: 8.35 (2.5-9.5) to 5.03 (2.5-6.8); motavizumab 100 mg/kg: 8.22 (5.5-9.7) to 4.25 (2.5-8.0); placebo: 8.02 (6.7-9.8) to 5.17 (2.5-7.3)]. Median (range) duration of hospitalization was 3.05 (0.8-16.0), 2.99 (1.0-25.0) and 2.88 (0.8-11.7) days for the motavizumab 30 mg/kg, motavizumab 100 mg/kg and placebo groups, respectively. Six (8%) motavizumab and 0 placebo recipients were admitted to the intensive care unit and 4 required mechanical ventilation. The incidence of wheezing episodes during the 12-month follow up was comparable for all 3 groups.Motavizumab had no appreciable effect on RSV viral load measured in the upper respiratory tract of children hospitalized for RSV lower respiratory tract infection. No differences were observed for duration of hospitalization, severity of illness measures or wheezing episodes during 12-month follow up in children treated with motavizumab or placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|